AbbVie Inc.
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 3, 2026Score 10/3089% above fair value
$288.84−6.05 (-2.05%)
Close on Nov 2, 2026Market cap $510.41BP/E 81.6Yield 2.30%
AbbVie Elahere (mirvetuximab soravtansine) by Quarter
Elahere (mirvetuximab soravtansine) — U.S. reported growth YoY (%) (%)
AbbVie Elahere (mirvetuximab soravtansine): 17.1% in Q2 2026, up 9.1 pts from a year earlier.
Latest, Q2 2026
17.1%
Period ended Jun 30, 2026
Change on a year earlier
+9.1 pts
8.0% in Q2 2025
History
5 quarters
Since Q2 2025
Sources
5
Documents cited below
Where the Q2 2026 figure comes from
“|| Elahere | 161 | 50 | 211 | 17.1”
Source: Form 8-K (abbv-20260630xexhibit991.htm, filed 2026-07-31) ↗
Reported in Form 8-K Key Product Revenues Schedule.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Elahere (mirvetuximab soravtansine) — U.S. reported growth YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 17.1% | +9.1 pts | Form 8-K (abbv-20260630xexhibit991.htm, filed 2026-07-31) ↗ |
| Q1 2026 | Mar 31, 2026 | -2.9% | – | Form 8-K (abbv-20260331xexhibit991.htm, filed 2026-04-29) ↗ |
| Q4 2025 | Dec 31, 2025 | 5.0% | – | Form 8-K (abbv-20251231xexhibit991.htm, filed 2026-02-04) ↗ |
| Q3 2025 | Sep 30, 2025 | 8.6% | – | Form 8-K (abbv-20250930xexhibit991.htm, filed 2025-10-31) ↗ |
| Q2 2025 | Jun 30, 2025 | 8.0% | – | Form 8-K (abbv-20250630xexhibit991.htm, filed 2025-07-31) ↗ |
Cite this data
StockData. (2026). AbbVie Elahere (mirvetuximab soravtansine) (%), quarterly Q2 2025–Q2 2026 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/elahere-us-rep-yoy
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.